The incidence and mortality of cervical cancer have declined significantly. However, cervical cancer is still a leading cause of cancer-related death in the female population worldwide; in 2006, there were approximately 500,000 patients newly diagnosed as cervical cancer and more than 280,000 deaths related to cervical cancer (World Health Organization). Although there have been many advances in screening, diagnostic and treatment modalities, the overall prognosis has not changed dramatically. Unfortunately, the mortality from cervical cancer approaches 50% (O'Toole et al. 2003) . The treatment of choice for cervical cancer is the radical surgery or radiation therapy for early-stage cervical cancer and the concurrent chemoradiation (CCRT) for advanced-stage cervical cancer. Chemotherapy alone has been relatively less important as a treatment option. However, the emphasis of recent chemotherapeutic strategies in cervical cancer is on improving outcomes related to the neoadjuvant chemotherapy for stage IB2-IIA with bulky mass and the palliative chemotherapy for recurrent or metastatic cervical cancer. The viability of chemotherapy in the treatment of malignant tumors depends on diverse factors, including cell type, degree of differentiation, cell cycle stage, and complex genomic alterations. Typically, however, the choice of a given chemotherapeutic drug is based on clinical trials that determine whether a drug is effective in large numbers of patients. This approach ignores variation to individual patient conditions (Sevin and Perras 1997) .
Many researchers have sought to develop in vitro methods that accurately predict the chemosensitivity of human tumors in vivo (Hoffman 1991a (Hoffman , 1993a Brown and Markman 1996) . However, none of these methods have yet been approved clinically because of the technical complexity and the difficulty of excluding ineffective drugs. Therefore, it would be desirable to establish an effective drug sensitivity test that overcomes such disadvantages. The histoculture drug response assay (HDRA) with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) endpoint has been proposed to detect individu-al chemosensitivity in many types of cancer (Hoffman 1991b; Robbins et al. 1994; Furukawa et al. 1995; Kubota et al. 1995; Furukawa et al. 2000) . Among the many available chemosensitivity tests, the HDRA is recognized as an appropriate method for the culture of many types of cancers because it allows cancer cells to be cultured in their natural three-dimensional architecture (Hoffman 1993b; Furukawa et al. 2000) . Recent studies have reported the clinical utility of the HDRA for patients with breast cancer and gastrointestinal cancer (Tanino et al. 2001; Kim et al. 2003) . In this study, we investigated the chemosensitivity or chemoresistance of uterine cervical cancer to several chemotherapeutic agents using the HDRA method.
Methods

Patients
Fresh tumor tissues from 67 patients with primary cervical cancer were evaluated using the HDRA at the Asan Medical Center, Seoul, Korea between January 2004 and March 2009. The data were obtained from 65 patients. We performed this study retrospectively and followed all guidelines for experimental investigation with human subjects required by the Institutional Review Board in Asan Medical Center. The median age of patients was 44 years (range, 25-74 years) and the median follow-up duration was 26.3 months (range, 1.6-52.7 months). The clinical stage by the International Federation of Gynecologists and Obstetricians (FIGO) was stage I of 80.0% (52/65) and stage IIA of 13.8% (9/65). Forty-seven patients were diagnosed with squamous cell carcinoma (72.3%), eleven were diagnosed with adenocarcinoma and seven were diagnosed with adenosquamous cell carcinoma. Two patients underwent primary CCRT and the others, including 52 patients requiring the adjuvant treatment, underwent surgery. Recurrence was reported in ten patients (Table 1) .
The HDRA
HDRA procedures were performed as previously reported by Furukawa et al. (2000) , with slight modifications. Fresh tumor tissues were obtained and carried to the laboratory within 4°C Hank's balanced salt solution (HBSS; Gibco, Gaithersburg, MD, USA). Tumor tissues were cut into approximately 10-15 mg pieces and viable parts were selected based on staining methods. They were placed onto collagen sponge gels (Gel Foam; Pharmacia & Upjohn, Kalamazoo, MI, USA). These sponge-gel cultures were then placed into 24-well plates with RPMI 1640 medium (Sigma-Aldrich, Inc., St. Louis, MO, USA) containing 20% fetal calf serum (FBS; U.S. Bio-technologies, Inc., Parkerford, PA, USA) and 100 µ g/mL of 100 units/mL penicillinstreptomycin (Gibco, Gaithersburg, MD, USA) for 24 hours. On the second day, the prepared chemotherapeutic agents were added and they were incubated for 72 hours. The concentration of each drug was decided on the basis of long-standing recommendations reflecting historical experimental usage, and were as follows; 50 g/mL carboplatin, 10 µ g/mL cisplatin, 75 µ g/mL paclitaxel, 75 µ g/mL docetaxel, 20 µ g/mL belotecan, 10 µ g/mL topotecan, 50 µ g/mL gemcitabine, 250 µ g/mL ifosfamide, 6 µ g/mL adriamycin and 50 µ g/mL etoposide. As a control, each tumor tissue was treated with phosphate-buffered saline (PBS) without chemotherapeutic agents.
MTT endpoint assay
After incubating for 3 days with each drugs, 100 µ L PBS containing 0.1 mg/dL collagenase (type I), 5 mg/dL MTT (Sigma-Aldrich, Inc., St Louis, MO, USA) and 50mM sodium succinate (Wako Pure Chemical Industries, Tokyo, Japan) were added to each well and they were incubated for an additional 4 hours. The resulting formazan crystals were then extracted from the tumor cultures with dimethyl sulfoxide (DMSO, Sigma-Aldrich, Inc., St.Louis, MO, USA). The optical density (OD) of DMSO-extracted formazan was measured with a microplate reader (SpectraMax 340PC, Molecular Devices, Sunnyvale, CA, USA) at 540 nm. The inhibition rate (IR) was calculated using the formula:
T is the mean absorbance of treated tumor/g and C is the mean absorbance of the control tumor/g.
Chemosensitivity was defined when tumor tissues had the inhibition rate of more than 30% for each chemotherapeutic agent. Because, at present, the approved definitions were absent, the cut-off value for chemosensitivity used in this study was calculated to compensate for experimental errors considering clinical outcomes over an extended period of time, based on the drug concentration used in our laboratory.
Statistics
One-way ANOVA test was used for comparing the chemosensitivity of each drug. Results were analyzed using SPSS 15.0 and p < 0.05 was considered significant.
Results
The results of in vitro chemosensitivity tests using the HDRA showed that five drugs were sensitive against uterine cervical cancer. Their inhibition rates were like these; 41.0% for carboplatin, 35.0% for cisplatin, 33.8% for paclitaxel, 41.4% for belotecan and 49.2% for topotecan (Fig. 1) . Among these agents, carboplatin combined with paclitaxel showed an inhibition rate of 54.0%, which was higher than any other single agent. Three single agents, carboplatin, topotecan and belotecan, and carboplatin combined with paclitaxel had significantly higher inhibition rates than that of cisplatin (35.0%), which is the traditional drug of choice in cervical cancer. Carboplatin, cisplatin, paclitaxel, belotecan and topotecan inhibited all histopathological types (i.e., squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma) by more than 30%. There were no differences in chemosensitivity according to histopathologic types (Table 2) . No agents showed significant differences with respect to FIGO stage.
Among ten patients who were experienced the recurrence after primary treatment, five underwent chemotherapy, two with CCRT and one with radiotherapy after recurrence. Platinum-based chemotherapy was performed as the initial choice and second line chemotherapeutic agents were selected on the basis of in vitro HDRA chemosensitivity data after confirming the recurrence (Table 3) . There were 5 patients who received chemotherapies based on platinum combined with paclitaxel (patient 2, 5, 7, 8 and 10 in Table  3 ). Their response and progression free survival had a tendency to follow the inhibition rate for paclitaxel, cisplatin and especially carboplatin. Patient 7 and 8, who showed more than 50% inhibition rate for carboplatin, had a long progression free duration after chemotherapies of paclitaxel and platinum. On the contrary, two patients with less than 30% inhibition rate for carboplatin did not respond to the chemotherapy (patient 5 and 10 in Table 3 ). There were 3 Fig. 1 . Results of in vitro chemosensitivity test using the HDRA in uterine cervical cancer. *significantly high inhibition rate comparing to CDDP ( p < 0.05) patients who received topotecan combined with cisplatin, however, the relation could not be revealed by the HDRA (patient 6, 7 and 10 in Table 3 ). Patient 1 showed a complete response and progression free survival of 9.5 months after primary adjuvant chemotherapy with ifosfamide and etoposide and they had been chemosensitive to the agents by the HDRA. However, despite the high inhibition rate for docetaxel and carboplatin by the HDRA, the clinical response to these chemotherapeutic agents was poor in patient 8. It is not yet possible to confirm the accurate relation between in vitro chemosensitivity data by the HDRA and clinical outcomes because of limited data from the small number of patients and their brief follow-up duration. Further evaluation is warranted to confirm the relationship between results of the HDRA and clinical responses.
Discussions
Cervical cancer usually presents with early stage disease and these early state diseases rarely relapse. For early state cancers, the treatments of choice include surgery, radiation therapy, or both, depending on patient and physician preference. Bulky stage IB2 and locally advanced (stages IIB-IVA) cervical cancers are treated with concurrent chemoradiation. Palliation with platinum based chemotherapy remains the standard of management for inoperable patients who have the advanced disease (Monk et al. 2009 ). Moore et al. (2003) reported that patients benefited from neoadjuvant chemotherapy, which led to better clinical response and operability rates. Dueñas-Gonzalez et al. (2003) found that the triple modality of neoadjuvant chemotherapy followed by radical hysterectomy and adjuvant radiation concurrent with cisplatin was a highly active treatment for locally advanced cervical carcinoma. They used three 21-day courses of carboplatin (AUC 6) and paclitaxel (175 mg/m 2 ), both administered by 3-hour infusion beginning on day 1 as neoadjuvant chemotherapy. Therefore, the selection of chemotherapeutic drugs is very important to achieve the neoadjuvant treatment and palliative treatment for recurrent and metastatic cervical cancer. However, actually, there are many problems encountered in devising chemotherapy for patients with advanced or recurrent cervical carcinoma, in point of view that the majority of such patients have already received prior radiation therapy with or without radical hysterectomy. Prior radiation therapy not only impairs the reserve function of bone marrow but also disturbs the delivery of the drug by interfering with vascular supply to the tumor bed (Shimizu 2000) . However, despite these problems, there is no doubt that chemotherapy is required in patients with recurrent cervical cancer who have already received radiation therapy. Therefore, the information regarding chemosensitivity is invaluable to patients with cervical cancers.
The chemosensitivity test in cancer patients started with the human tumor clonogenic assay (HTCA) in 1970's in order to determine the most appropriate drug for treating individual patients (Salmon et al. 1978) . Currently, several chemosensitivity tests are clinically applicable; for examples, the MTT assay (Cole 1986) , the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) assay (O'Toole et al. 2003) , the HDRA (Hoffman 1991b (Hoffman , 1993a Robbins et al. 1994; Furukawa et al. 1995; Brown and Markman 1996) , and collagen gel droplet-embedded culture drug sensitivity test (CD-DST) (Inaba et al. 1996; Takamura et al. 2002) . The monolayer culture MTT assay is based on the reduction of MTT by mitochondrial succinic dehydrogenase which is in living cells. This MTT assay has been used in the chemotherapeutic agents screening program of the National Cancer Institute (NCI) since 1991 and was reported to show the accuracy in more than 90% of patients (Kim et al. 2003) . The MTS assay is a modified, improved version of the MTT assay, and works on the principle that the mitochondrial dehydrogenase enzyme reduces the salt to a colored formazan product that can be read directly at 492 nm. However, MTT and MTS assays were carried out as a single-cell suspension, therefore, the cell to cell contact is eliminated and these tests are significantly influenced by the presence of contaminating fibroblasts (Furukawa et al. 1995) . Another problem of monolayer cultures is that the viability of tumor cells decreases more easily during culture under controlled conditions. The chemosensitivity demonstrated in the HDRA, utilizing a three-dimensional soft agar substrate, may be more accurately mimic the in vivo response. The HDRA has been used in a number of cancers with sensitivity of nearly 100%, specificity of 70-90% and clinical correlation of 80-90% (Furukawa et al. 1995; Tanino et al. 2001 ). There are some reports to show a survival benefit of in vitro chemosensitivity tests in patients with gastrointestinal cancer, breast or ovarian cancer (Bosanquet 1993; Brown and Markman 1996; Fruehauf 2002) .
There are only a few studies on chemosensitivity using MTT or MTS assays in uterine cervical cancer. Using the MTT assay, Xiao et al. (2007) reported that cervical cancer cells were more sensitive to liposomal paclitaxel (IR: 56.56 ± 26.62%), taxol (IR: 55.66 ± 23.28%) and carboplatin (IR: 46.81 ± 15.67%) than to the other drugs. Clinically, Tinker et al. (2005) reported that carboplatin (AUC 5-6) and paclitaxel (155-175 mg/m 2 ) regimens were highly effective against advanced and recurrent squamous cell carcinoma of the cervix. Consistent with previous reports, our study showed that carboplatin, cisplatin, paclitaxel, belotecan and topotecan had chemosensitivity presenting the inhibition rate of more than 30%. Interestingly, our HDRA data showed that carboplatin combined with paclitaxel had a 54.0% inhibition rate, which was the highest in all used chemotherapeutic agents. There are no comparable in vitro chemosensitivity data for topotecan and belotecan in cervical cancer. However, clinically combined chemotherapy with topotecan and cisplatin demonstrated the better response rate and progression-free survival than cisplatin alone (Long et al. 2005) .
The National Comprehensive Cancer Network (NCCN) has developed clinical chemotherapy guidelines for recurrent or metastatic cervical cancer (Practice Guidelines in Oncology-v.1. 2008) . Cisplatin, carboplatin, paclitaxel, topotecan and gemcitabine are recommended as first-line single or combination therapies and docetaxel, ifosphamide, vinorelbine, irinotecan, epirubicin, mitomycin and 5-FU are considered as second-line therapies. However, with the exception of single or combined cisplatin, carboplatin and paclitaxel therapy, most regimens lack a uniform NCCN consensus based on primary evidence, including clinical experience. In our study, not only carboplatin and carboplatin combined with paclitaxel, but also topotecan and belotecan showed higher inhibition rates against cervical cancer cells than cisplatin, and adriamycin had very high inhibition rates in patients of adenocarcinoma.
Chemotherapy should be based on individual cellular or genetic differences. The HDRA, which reveals the chemosensitivity for diverse drugs, could realize the individualized chemotherapeutic strategies, although it has not been widely accepted in uterine cervical cancer because of the insufficient clinical data. The HDRA is an outstanding assay for analyzing chemosensitivity and could provide information that is invaluable for the design of specific, individualized treatments in patients with uterine cervical cancer. Further randomized controlled studies might validate the clinical benefit of the HDRA.
